Small molecule · Inhibitor of SARS-CoV-2 main protease (Mpro, 3CL) · developed by Traws Pharma
Ratutrelvir (83-0060) is a covalent inhibitor of the SARS-CoV-2 main protease (Mpro, also called 3CL). It is being studied in COVID-19.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07157007 | Phase 2 | COVID - 19 | Completed | TRAW |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COVID - 19
Updated Nov 1, 2026. Something wrong or missing? Report it on the TRAW page.
See TRAW's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TRAW catalysts and pipeline →